The FDA paused an Eli Lilly clinical trial for a COVID-19 antibody drug due to safety concerns and quality control violations at a New Jersey manufacturing plant. Inspectors found that data regarding manufacturing processes had been deleted and not properly audited. While the company claims the deletions were unrelated to the specific COVID drug, the timing of the pause followed President Trump's public endorsement of the treatment.
